http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 06 Jul 2026 12:40:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Press+Releases/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026: </p><ul class="bwlistdisc"> <li> 676 shares </li> <li> 1 173 521 € </li> </ul><p> Over the period from 01/01/2026 to 30/06/2026, a total of: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwvertalignb bwpadl0 bwsinglebottom bwrightsingle" rowspan="1" colspan="1" /> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of executions</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Number of shares</b> </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> <b>Traded volume in EUR</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0" rowspan="1" colspan="1"><p http://www.streetinsider.com/Business+Wire/Medincell%3A+Half-Year+Liquidity+Contract+Statement/26734474.html Mon, 06 Jul 2026 12:40:00 -0400 A.26590232 A.27499954 A.33961688 MEDCL O.00322408 O.00401804 O.01202324 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html <p> <b>A year marked by solid execution, with</b> </p><ul class="bwlistdisc"> <li> <b>Continued UZEDY® ramp-up, supporting royalty growth</b> </li> <li> <b>Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva</b>1 </li> <li> <b>The first AbbVie program progressing toward the initiation of clinical development</b> </li> <li> <b>The expansion of both partnered and internal R&amp;D pipelines</b> </li> <li> <b>Continued strengthening of the technology platform</b> </li> </ul> <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td colspan="3" class="bwwidth11 bwsinglebottom" rowspan="1"><b>Key Financial Highlights</b></td> </tr> <tr> <td class="bwwidth11" rowspan="1" colspan="1" /> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> </tr> <tr> <td class="bwwidth11 bwvertalignt bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> <b>Total revenues</b> </p> </td> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88 bwalignl" rowspan="1" http://www.streetinsider.com/Press+Releases/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html Tue, 16 Jun 2026 11:45:00 -0400 MEDCL O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html <p> <b>A year marked by solid execution, with</b> </p><ul class="bwlistdisc"> <li> <b>Continued UZEDY® ramp-up, supporting royalty growth</b> </li> <li> <b>Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva</b>1 </li> <li> <b>The first AbbVie program progressing toward the initiation of clinical development</b> </li> <li> <b>The expansion of both partnered and internal R&amp;D pipelines</b> </li> <li> <b>Continued strengthening of the technology platform</b> </li> </ul> <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td colspan="3" class="bwwidth11 bwsinglebottom" rowspan="1"><b>Key Financial Highlights</b></td> </tr> <tr> <td class="bwwidth11" rowspan="1" colspan="1" /> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> </tr> <tr> <td class="bwwidth11 bwvertalignt bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> <b>Total revenues</b> </p> </td> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88 bwalignl" rowspan="1" http://www.streetinsider.com/Press+Releases/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html Tue, 16 Jun 2026 11:45:00 -0400 MEDCL O.01384798 http://www.streetinsider.com/Business+Wire/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html <p> <b>A year marked by solid execution, with</b> </p><ul class="bwlistdisc"> <li> <b>Continued UZEDY® ramp-up, supporting royalty growth</b> </li> <li> <b>Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva</b>1 </li> <li> <b>The first AbbVie program progressing toward the initiation of clinical development</b> </li> <li> <b>The expansion of both partnered and internal R&amp;D pipelines</b> </li> <li> <b>Continued strengthening of the technology platform</b> </li> </ul> <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td colspan="3" class="bwwidth11 bwsinglebottom" rowspan="1"><b>Key Financial Highlights</b></td> </tr> <tr> <td class="bwwidth11" rowspan="1" colspan="1" /> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> </tr> <tr> <td class="bwwidth11 bwvertalignt bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> <b>Total revenues</b> </p> </td> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88 bwalignl" rowspan="1" http://www.streetinsider.com/Business+Wire/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html Tue, 16 Jun 2026 11:45:00 -0400 MEDCL O.01384798 http://www.streetinsider.com/Business+Wire/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html <p> <b>A year marked by solid execution, with</b> </p><ul class="bwlistdisc"> <li> <b>Continued UZEDY® ramp-up, supporting royalty growth</b> </li> <li> <b>Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva</b>1 </li> <li> <b>The first AbbVie program progressing toward the initiation of clinical development</b> </li> <li> <b>The expansion of both partnered and internal R&amp;D pipelines</b> </li> <li> <b>Continued strengthening of the technology platform</b> </li> </ul> <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td colspan="3" class="bwwidth11 bwsinglebottom" rowspan="1"><b>Key Financial Highlights</b></td> </tr> <tr> <td class="bwwidth11" rowspan="1" colspan="1" /> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> </tr> <tr> <td class="bwwidth11 bwvertalignt bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> <b>Total revenues</b> </p> </td> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88 bwalignl" rowspan="1" http://www.streetinsider.com/Business+Wire/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html Tue, 16 Jun 2026 11:45:00 -0400 MEDCL O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798